ReviewNeurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics2007
Talampanel.
Review in Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 75 citations in OpenAlex.
- Phase 2 trial of talampanel, a glutamate receptor inhibitor, for adults with recurrent malignant gliomas.Cancer · 2010Trial
- Talampanel with standard radiation and temozolomide in patients with newly diagnosed glioblastoma: a multicenter phase II trial.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2009Trial
- Epilepsy as a Disorder of Neuroimmune Metabolism: The Kynurenine Pathway as a Link Between Cognitive and Psychiatric Dysfunction.Biomolecules · 2026Review
- Review
- Disrupted glutamate homeostasis as a target for glioma therapy.Pharmacological reports : PR · 2024Review
- Deciphering the Biophysical Properties of Ion Channel Gating Pores by Coumarin-Benzodiazepine Hybrid Derivatives: Selective AMPA Receptor Antagonists.Molecular neurobiology · 2024Article
- Antitumor Potential of Antiepileptic Drugs in Human Glioblastoma: Pharmacological Targets and Clinical Benefits.Biomedicines · 2023Review
- Anti-tumor effects of perampanel in malignant glioma cells.Oncology letters · 2022Article
- Synergistic Effect of Perampanel and Temozolomide in Human Glioma Cell Lines.Journal of personalized medicine · 2021Article
- Radiosensitizers in the temozolomide era for newly diagnosed glioblastoma.Neuro-oncology practice · 2020Review
- The AMPA receptor antagonist perampanel robustly rescues amyotrophic lateral sclerosis (ALS) pathology in sporadic ALS model mice.Scientific reports · 2016Article
- Mechanism-based design of 2,3-benzodiazepine inhibitors for AMPA receptors.Acta pharmaceutica Sinica. B · 2015Review
- Treatment of status epilepticus with ketamine, are we there yet?CNS neuroscience & therapeutics · 2013Review
- Mechanism of inhibition of the GluA2 AMPA receptor channel opening by talampanel and its enantiomer: the stereochemistry of the 4-methyl group on the diazepine ring of 2,3-benzodiazepine derivatives.ACS chemical neuroscience · 2013Article
- Unique biology of gliomas: challenges and opportunities.Trends in neurosciences · 2012Review
- Towards personalized therapy for patients with glioblastoma.Expert review of anticancer therapy · 2011Review
- Talampanel reduces the level of motoneuronal calcium in transgenic mutant SOD1 mice only if applied presymptomatically.Amyotrophic lateral sclerosis : official publication of the World Federation of Neurology Research Group on Motor Neuron Diseases · 2011Article
- AMPA receptor regulation at the mRNA and protein level in rat primary cortical cultures.PloS one · 2011Article
- Glutamate receptor ion channels: structure, regulation, and function.Pharmacological reviews · 2010Review
- A series of structurally novel heterotricyclic alpha-amino-3-hydroxyl-5-methyl-4-isoxazole-propionate receptor-selective antagonists.British journal of pharmacology · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Talampanel is a novel anticonvulsant that acts as an allosteric inhibitor of the AMPA receptor. Talampanel has a broad spectrum of action in animal models of epilepsy and neuroprotection. Clinical experience to date has been able to show effectiveness in reduction of seizures in patients with refractory partial seizures.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.